Prevention of tumor metastasis formation by anti-variant CD44
- PMID: 8426113
- PMCID: PMC2190906
- DOI: 10.1084/jem.177.2.443
Prevention of tumor metastasis formation by anti-variant CD44
Abstract
A splice variant of CD44 (CD44v) originally discovered on metastases of a rat pancreatic adenocarcinoma (BSp73ASML) has been shown by transfection to confer metastatic behavior to nonmetastatic tumor cells (Günthert U., M. Hofmann, W. Rudy, S. Reber, M. Zöller, I. Haussmann, S. Matzku, A. Wenzel, H. Ponta, and P. Herrlich. 1991. Cell. 65:13). A monoclonal antibody (mAb), 1.1ASML, to the metastasis-specific domain of the CD44v molecule retards growth of lymph node and lung metastases of the metastatic tumor line BSp73ASML, and can efficiently prevent formation of metastases by the transfected line. The antibody is only effective when given before lymph node colonization. Anti-CD44v does not downregulate the expression of CD44v, and prevention of metastatic growth by anti-CD44v is not due to activation of any kind of immune defense. We suggest that the mAb interferes with proliferation of metastasizing tumor cells in the draining lymph node, most probably by blocking a ligand interaction. The interference with metastatic spread will greatly facilitate the exploration of the function of CD44v and, in particular, may also open new strategies for the therapy of human metastases.
Similar articles
-
CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance.Mol Cancer Res. 2009 Feb;7(2):168-79. doi: 10.1158/1541-7786.MCR-08-0207. Epub 2009 Feb 10. Mol Cancer Res. 2009. PMID: 19208744
-
A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells.Cancer Res. 1993 Apr 1;53(7):1516-21. Cancer Res. 1993. PMID: 8453616
-
Retardation of metastatic tumor growth after immunization with metastasis-specific monoclonal antibodies.Int J Cancer. 1990 Nov 15;46(5):919-27. doi: 10.1002/ijc.2910460528. Int J Cancer. 1990. PMID: 2228320
-
CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation.J Mol Med (Berl). 1995 Sep;73(9):425-38. doi: 10.1007/BF00202261. J Mol Med (Berl). 1995. PMID: 8528746 Review.
-
[Expression of variant CD44 in colorectal cancer and its relationship to liver metastasis].Nihon Geka Gakkai Zasshi. 1998 Jul;99(7):409-14. Nihon Geka Gakkai Zasshi. 1998. PMID: 9742519 Review. Japanese.
Cited by
-
Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma.Am J Pathol. 1999 Nov;155(5):1427-32. doi: 10.1016/S0002-9440(10)65455-7. Am J Pathol. 1999. PMID: 10550296 Free PMC article.
-
Expression of CD44v6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.Oncol Lett. 2011 May;2(3):429-434. doi: 10.3892/ol.2011.264. Epub 2011 Mar 8. Oncol Lett. 2011. PMID: 22866099 Free PMC article.
-
Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance.Am J Pathol. 2011 Mar;178(3):956-63. doi: 10.1016/j.ajpath.2010.11.077. Am J Pathol. 2011. PMID: 21356346 Free PMC article. Review.
-
Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer.World J Gastroenterol. 2011 Jul 21;17(27):3220-8. doi: 10.3748/wjg.v17.i27.3220. World J Gastroenterol. 2011. PMID: 21912471 Free PMC article.
-
CD44 and the adhesion of neoplastic cells.Mol Pathol. 1997 Apr;50(2):57-71. doi: 10.1136/mp.50.2.57. Mol Pathol. 1997. PMID: 9231152 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous